CREBBP
MOLECULAR TARGETCREB binding lysine acetyltransferase
CREBBP (CREB binding lysine acetyltransferase) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CREBBP
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | epigalocatechin gallate | 5.40 | 220 |
| 2 | molibresib | 3.81 | 44 |
| 3 | a 485 | 2.83 | 16 |
| 4 | gsk046 | 2.40 | 10 |
| 5 | gsk620 | 2.30 | 9 |
| 6 | azd 5153 | 2.20 | 8 |
| 7 | inobrodib | 2.20 | 8 |
| 8 | ischemin | 2.20 | 8 |
| 9 | gsk778 | 2.08 | 7 |
| 10 | Papaverine | 1.10 | 2 |
| 11 | Colchicine | 0.69 | 1 |
| 12 | Etazolate | 0.69 | 1 |
| 13 | Nocodazole Nocodazole is | 0.69 | 1 |
About CREBBP as a Drug Target
CREBBP (CREB binding lysine acetyltransferase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented CREBBP interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CREBBP inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.